Market
Which Orbis Medicines drug will enter Phase II trials by end of 2025?
2
Orbis Medicines•Danish•Novo Holdings•Sevan Habeshian•Christian Heinis•New Enterprise Associates•NEA•Eli Lilly•Cormorant•Forbion•Orbis•Morten Graugaard Døssing
Resolution / Starting Odds
Drug A • 25%
Drug B • 25%
Drug C • 25%
None • 25%
Company press releases or clinical trial registries
Story
Danish Biotech Orbis Medicines Raises €90 Million for Oral Macrocycle Drugs Targeting Biologic Therapies
Jan 6, 2025, 04:14 PM
Orbis Medicines, a Danish biotechnology startup, has raised €90 million (approximately $93 million) in a Series A funding round to develop oral macrocycle drugs. The company, incubated by Novo Holdings and co-founded by Sevan Habeshian and Christian Heinis, aims to transform popular biologic therapies into oral medications using macrocyclic peptides, targeting validated blockbuster biologic targets. The funding round was led by New Enterprise Associates (NEA) and included investments from Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion. Orbis, which emerged from stealth with €26 million in seed funding last year, is now led by CEO Morten Graugaard Døssing, who previously served as executive chair of the company's board.
View original story
Similar markets
Positive results leading to Phase 2 • 25%
Other outcome • 25%
Negative results halting development • 25%
Neutral results requiring further study • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
No improvement • 25%
Significant improvement • 25%
Moderate improvement • 25%
Worsening condition • 25%
Moderate improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
No improvement • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial extended • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Other • 25%